Back
Zealand Pharma share buyback reaches DKK 699.6 million after week-31 purchases

Zealand Pharma share buyback reaches DKK 699.6 million after week-31 purchases

The biotech company repurchased 147,000 shares for DKK 44.5 million during the week, taking total acquisitions under its 2026 buyback programme to 2.339 million shares.

Fact Check
Festi hf.'s own regulatory announcement confirms all specifics of the claim: 150,000 shares bought in week 31 for ISK 46,462,500 (matching '46.46 million'), cumulative total reaching exactly 1,000,000 shares ('1 million shares'), treasury holdings rising to 1.50% of issued share capital, and the programme announced on 1 July 2026 ('July 1'). The claim's characterization of Festi as an Icelandic retailer is consistent. Every quantitative and temporal detail matches the primary source.
    Reference: 1
Summary

Zealand Pharma A/S said transactions completed between July 27 and July 31 under its 2026 share buyback programme lifted cumulative purchases to 2,339,000 shares for a total of DKK 699,551,800. The company bought 147,000 shares during week 31 for DKK 44,545,390 on Nasdaq Copenhagen. The programme, announced on May 7, 2026, allows Zealand Pharma to repurchase shares for up to DKK 1.3 billion, with a maximum of 7,152,557 shares. It began on May 7 and is due to be completed no later than October 31, 2026. Danske Bank is acting as lead manager and makes trading decisions independently of the company. The buyback is being carried out under the EU Market Abuse Regulation and the Safe Harbour Regulation. After the latest purchases, Zealand Pharma held 3,209,482 treasury shares, equal to about 4.48% of its share capital. The company has 71,578,758 shares outstanding, each with a nominal value of DKK 1.

Terms & Concepts
  • treasury shares: Shares a company has repurchased and now holds itself instead of leaving them in the market.
  • Market Abuse Regulation: EU rules that govern market conduct, including conditions for company share repurchase programmes.
  • Safe Harbour Regulation: An EU framework that sets conditions for buyback programmes to help protect issuers from market abuse concerns.